Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:7/13/2018
Start Date:October 7, 2008
End Date:December 31, 2020

Use our guide to learn which trials are right for you!

A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy With Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/Neu Positive Metastatic Breast Cancer

RATIONALE: HER2/neu is a receptor (protein) which is found in unusually high amounts in
approximately 1 in 5 cancer patients. Scientific evidence suggests that having high amounts
of the HER2/neu receptor is important for breast cancer to grow and spread. Women with
previously untreated metastatic breast cancer (breast cancer that has spread to other organs)
and with high levels of the HER2/neu receptor receive as their usual treatment chemotherapy
with one of the approved chemotherapy drugs paclitaxel or docetaxel (called "taxanes")
together with another approved drug called "trastuzumab". Chemotherapy drugs, such as
paclitaxel and docetaxel, work either by killing tumour cells or by stopping them from
dividing. Trastuzumab is an antibody that is given through a vein in the arm and it works by
specifically "targeting" the HER2/neu i.e. it attaches to it and "turns it off". Although
some of the patients who receive this taxane plus trastuzumab treatment feel better for some
months, the cancer usually starts to grow again. Lapatinib is a new drug. Like trastuzumab,
it also works by specifically "targeting" the HER2/neu receptor, but it does so in a
different way. Lapatinib is not an antibody. It is a pill that is taken daily by mouth.
Because lapatinib works in a different way than trastuzumab, it may be worse, as good as or
better than trastuzumab in keeping metastatic HER/neu positive cancer from growing. However,
this is not known.

Purpose: This randomized Phase III trial is comparing chemotherapy (a taxane) given together
with lapatinib with chemotherapy (a taxane) given together with trastuzumab in women with
HER2/neu positive breast cancer.

OBJECTIVES:

Primary

- To compare the progression-free survival of women with HER2/neu-positive metastatic
breast cancer treated with taxane-based chemotherapy in combination with lapatinib
ditosylate or trastuzumab (Herceptin®).

Secondary

- To compare the overall survival.

- To compare the time to CNS metastases at the time of first progression.

- To compare the incidence rates of CNS metastases at the time of progression.

- To compare the overall objective response rate (complete or partial response), time to
response, and duration of response in patients with measurable disease at baseline.

- To compare the clinical benefit response rate.

- To compare the adverse event profile.

- To compare the quality of life.

- To compare clinical outcomes using biomarker changes in biological samples.

- To compare health economics, including healthcare utilization and health utilities.

OUTLINE: This is a multicenter study. Patients are stratified according to prior
neoadjuvant/adjuvant anti-HER2/neu-targeted therapy (yes vs no), prior neoadjuvant/adjuvant
taxane chemotherapy (yes vs no), planned taxane therapy (paclitaxel vs docetaxel), and liver
metastasis (yes vs no). Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive either paclitaxel IV on days 1, 8, and 15; treatment with
paclitaxel repeats every 4 weeks for 6 courses in the absence of disease progression or
unacceptable toxicity. Alternatively, patients may receive docetaxel IV on day 1;
treatment with docetaxel repeats every 3 weeks for 8 courses in the absence of disease
progression or unacceptable toxicity. Patients on docetaxel also receive filgrastim
(G-CSF) according to institutional standard. All patients receive oral lapatinib
ditosylate once daily during taxane treatment and continue after completion of taxane
treatment, in the absence of disease progression or unacceptable toxicity.

- Arm II: Patients receive paclitaxel IV on days 1, 8, and 15 and trastuzumab (Herceptin®)
IV on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for 6 courses in the
absence of disease progression or unacceptable toxicity. Alternatively, patients may
receive docetaxel IV and trastuzumab IV on day 1. Treatment repeats every 3 weeks for 8
courses in the absence of disease progression or unacceptable toxicity. After completion
of taxane chemotherapy and trastuzumab, all patients receive trastuzumab alone IV once
every 3 weeks in the absence of disease progression or unacceptable toxicity.

Formalin-fixed paraffin-embedded tissue samples are analyzed for ER, PgR, EGFR, CK5/6, Ki67,
and other molecular biomarkers by tissue microarray and immunohistochemistry.

Patients complete quality of life questionnaires (EORTC QLQ-C30 and a Trial Specific
Checklist) at baseline, every 12 weeks for 96 weeks, and then every 24 weeks until disease
progression.

After completion of study treatment, patients are followed at 4 weeks post treatment, and
then every 12 weeks thereafter (counting from the beginning of study therapy).

DISEASE CHARACTERISTICS:

- Histologically confirmed adenocarcinoma of the breast

- Metastatic (stage IV) disease at primary diagnosis or at relapse after curative intent
therapy

- Local or central laboratory confirmedHER2/neu* overexpressing and/or amplified disease
in the invasive component of the primary or metastatic lesion as defined by the
following:

- 3+ overexpression (in > 30% of invasive tumor cells) by immunohistochemistry
(IHC)

- 2+ or 3+ overexpression (in ≤ 30% of invasive tumor cells) by IHC AND
demonstrates HER2/neu gene amplification by fluorescence in situ hybridization
(FISH) or chromogenic in situ hybridization (CISH)

- HER2/neu gene amplification by FISH/CISH (> 6 HER2/neu gene copies per nucleus,
or a FISH/CISH ratio [HER2 gene copies to chromosome 17 signals] of ≥ 2.2) NOTE:
*Patients with a negative or equivocal overall result (FISH/CISH ratio of < 2.2,
≤ 6.0 HER2/neu gene copies per nucleus, or staining scores of 0, 1+, 2+, or 3+
[in ≤ 30% of neoplastic cells] by IHC) are not eligible

- Formalin-fixed paraffin-embedded tumor specimen available

- No CNS metastases (including leptomeningeal involvement)

- Hormone receptor status not specified

PATIENT CHARACTERISTICS:

- Menopausal status not specified

- ECOG performance status 0-2

- Life expectancy > 6 months

- Absolute granulocyte count > 1,500/mm³

- Platelet count > 75,000/mm³

- Hemoglobin > 10 g/dL

- Serum creatinine ≤ 2.0 times upper limit of normal (ULN)

- Total bilirubin ≤ 1.5 times ULN (< 3 times ULN for patients with Gilbert's disease)

- AST and/or ALT ≤ 2.5 times ULN (< 5 times ULN for patients planning to receive
paclitaxel-based therapy)

- LVEF ≥ 50% by MUGA or ECHO

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Must be accessible for study treatment and follow-up

- No history of other malignancies, except adequately treated ductal carcinoma in situ
or lobular carcinoma in situ, adequately treated nonmelanoma skin cancer, curatively
treated carcinoma in situ of the cervix, or other curatively treated solid tumor
(non-breast) with no evidence of disease for ≥ 5 years

- No serious cardiac illness or condition including, but not limited to, any of the
following:

- History of documented congestive heart failure

- Systolic dysfunction (LVEF < 50%)

- High-risk uncontrolled arrhythmias (i.e., ventricular tachycardia, high-grade
atrioventricular block, or supraventricular arrhythmias that are not adequately
rate-controlled)

- Unstable angina pectoris requiring anti-anginal medication

- Clinically significant valvular heart disease

- Evidence of transmural infarction on ECG

- Inadequately controlled hypertension (i.e., systolic blood pressure [BP] > 180 mm
Hg or diastolic BP > 100 mm Hg)

- New York Heart Association class III-IV functional status

- No serious illness or medical condition that would not allow the patient to be managed
according to the protocol including, but not limited to, any of the following:

- History of significant neurologic or psychiatric disorder that would impair the
ability to obtain informed consent or limit compliance with study requirements

- Active uncontrolled infection

- Serious or nonhealing wound, ulcer, or bone fracture

- No peripheral neuropathy ≥ grade 2

- No gastrointestinal (GI) tract disease resulting in an inability to take oral
medication including, but not limited to, any of the following:

- Malabsorption syndrome

- Requirement for IV alimentation

- Uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative
colitis)

- No history of allergic or hypersensitivity reactions to any study drug or their
excipients or to compounds with similar chemical composition to any of the study drugs

- Prior allergic reactions to taxanes are allowed provided they were adequately
treated and, according to the treating physician, would not prohibit further
treatment with taxanes

PRIOR CONCURRENT THERAPY:

- Recovered from all prior therapy

- No prior chemotherapy, immunotherapy, biological therapy, or anti-HER2/neu-targeted
therapy for recurrent or metastatic breast cancer

- At least 12 months since prior chemotherapeutic agents, including taxanes, in the
neoadjuvant or adjuvant setting

- At least 12 months since prior anti-HER2/neu-targeted therapy in the neoadjuvant or
adjuvant setting

- Prior treatment with endocrine therapy in the neoadjuvant, adjuvant, or metastatic
setting allowed

- At least 2 weeks since prior radiotherapy in the adjuvant or metastatic setting

- Prior radiotherapy to a solitary metastatic lesion allowed provided there is
documented disease progression after completion of radiotherapy

- More than 30 days (or 5 half-lives) since prior investigational drugs

- At least 7 days since prior and no concurrent CYP3A4 inhibitors (6 months for
amiodarone)

- At least 14 days since prior and no concurrent CYP3A4 inducers

- No prior surgical procedures affecting absorption (e.g., resection of stomach or small
bowel)

- No concurrent palliative radiotherapy

- No other concurrent anticancer treatment

- No other concurrent investigational drugs for breast cancer
We found this trial at
53
sites
Munster, Indiana 46321
?
mi
from
Munster, IN
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Augusta, Georgia 30904
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Bellevue, Washington 98004
?
mi
from
Bellevue, WA
Click here to add this to my saved trials
Berkeley, California 94705
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
Bozeman, Montana 59718
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Canton, Ohio 44718
?
mi
from
Canton, OH
Click here to add this to my saved trials
Capital Federal, Buenos Aires
?
mi
from
Capital Federal,
Click here to add this to my saved trials
Chesapeake, Virginia 23320
?
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Chicago, Illinois 60612
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Colorado Springs, Colorado 80907
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Columbia, South Carolina 29201
?
mi
from
Columbia, SC
Click here to add this to my saved trials
Cooperstown, New York 13326
?
mi
from
Cooperstown, NY
Click here to add this to my saved trials
Denver, Colorado 80262
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denville, New Jersey 07834
?
mi
from
Denville, NJ
Click here to add this to my saved trials
Evansville, Indiana 47713
?
mi
from
Evansville, IN
Click here to add this to my saved trials
Goshen, Indiana 46526
?
mi
from
Goshen, IN
Click here to add this to my saved trials
Grand Island, Nebraska 68803
?
mi
from
Grand Island, NE
Click here to add this to my saved trials
Greensboro, North Carolina 27401
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
Greenwich, Connecticut 06830
?
mi
from
Greenwich, CT
Click here to add this to my saved trials
Highland, California 92346
?
mi
from
Highland, CA
Click here to add this to my saved trials
Hot Springs, Arkansas 71913
?
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Kearney, Nebraska 68848
?
mi
from
Kearney, NE
Click here to add this to my saved trials
Kirkland, Washington 98034
?
mi
from
Kirkland, WA
Click here to add this to my saved trials
Kissimmee, Florida 34741
?
mi
from
Kissimmee, FL
Click here to add this to my saved trials
Lawrenceville, Georgia 30046
?
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Loxahatchee Groves, Florida 33470
?
mi
from
Loxahatchee Groves, FL
Click here to add this to my saved trials
Memphis, Tennessee 38120
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Milwaukee, Wisconsin 53209
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Montebello, California 90640
?
mi
from
Montebello, CA
Click here to add this to my saved trials
Mount Vernon, Washington 98273
?
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
New Albany, Indiana 47150
?
mi
from
New Albany, IN
Click here to add this to my saved trials
New Port Richey, Florida 34653
?
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Oak Lawn, Illinois 60453
?
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
Parsippany, New Jersey 07054
?
mi
from
Parsippany, NJ
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15224
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Portland, Oregon 97228
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Post Falls, Idaho 83854
?
mi
from
Post Falls, ID
Click here to add this to my saved trials
Salem, Virginia 24153
?
mi
from
Salem, VA
Click here to add this to my saved trials
Savannah, Georgia 31406
?
mi
from
Savannah, GA
Click here to add this to my saved trials
Seattle, Washington 98103
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Sequim, Washington 98382
?
mi
from
Sequim, WA
Click here to add this to my saved trials
Southington, Connecticut 06489
?
mi
from
Southington, CT
Click here to add this to my saved trials
Stamford, Connecticut 06905
?
mi
from
Stamford, CT
Click here to add this to my saved trials
Tacoma, Washington 98405
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
Towson, Maryland 21204
?
mi
from
Towson, MD
Click here to add this to my saved trials
Trumbull, Connecticut 06611
?
mi
from
Trumbull, CT
Click here to add this to my saved trials
Tucson, Arizona 85745
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Waterbury, Connecticut 06708
?
mi
from
Waterbury, CT
Click here to add this to my saved trials
Wenatchee, Washington 98801
?
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Wheaton, Maryland 20902
?
mi
from
Wheaton, MD
Click here to add this to my saved trials
Wooster, Ohio 44691
?
mi
from
Wooster, OH
Click here to add this to my saved trials